Sequencing systemic therapies in metastatic castration-resistant prostate cancer

Cancer Control

Volumn 20, Issue 3, 2013, Pages 181-187

  Liu, Jane Jijun ^a   Zhang, Jingsong ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPILIMUMAB; KETOCONAZOLE; LENALIDOMIDE; MITOXANTRONE; ORTERONEL; PLACEBO; PREDNISONE; TAK-700; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DEATH; DIARRHEA; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; HOT FLUSH; HUMAN; HYPOCALCEMIA; IMMUNOTHERAPY; INFECTION; JAW OSTEONECROSIS; METASTASIS; METASTASIS FREE SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; SYSTEMIC THERAPY; VOMITING; CLINICAL TRIAL (TOPIC); MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84879548824     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481302000306     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-1192.
3. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol. 2005;23(32): 8247-8252.
4. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12):3876-3883.
5. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
6. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-1197.
7. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241-1246.
8. Barrie SE, Haynes BP, Potter GA, et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P450(17alpha) inhibitors. J Steroid Biochem Mol Biol. 1997;60(5-6):347-351.
9. Jarman M, Barrie SE, Llera JM. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem. 1998;41(27):5375-5381.
10. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38(13): 2463-2471.
11. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2): 138-148.
12. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J Clin Oncol. 2010;28(15 suppl):254s. Abstract 3084.
13. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324(5928):787-790.
14. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000;18(23):3894-3903.
15. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000;6(6):2175-2182.
16. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002;117(3):471-477.
17. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5): 411-422.
18. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-3679.
19. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26(32):5275-5283.
20. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer. 2007;110(12):2614-2627.
21. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma? Oncologist. 2009;14(8):848-861.
22. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58(5):823-830.
23. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
24. Tollefson MK, Karnes RJ, Thompson RH, et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. In: Program and abstracts of the American Society of Clinical Oncology 2010 Genitourinary Cancers Symposium; March 5-7, 2010; San Francisco, CA. Abstract 168.
25. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-1105.
26. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
27. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
28. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol. 2010;28(18s). Abstract LBA4511.
29. Celgene discontinues Revlimid prostate cancer trial. http://www.pharmatimes.com/Article/11-11-23/Celgene_discontinues_Revlimid_prostate_cancer_trial.aspx. Accessed April 11, 2013.
30. Araujo JC, Trudel GC, Saad F, et al. Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized phase III READY trial. Presented at the 2013 Genitourinary Cancers Symposium, February 14-16, 2013, Orlando, FL. J Clin Oncol. 2013;31(6 Feb 20 suppl):LBA8. Abstract.
31. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-1154.
32. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80-100.
33. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191-1200.
34. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377-387.
35. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
36. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
37. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.
38. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39-46.
39. Bauman G, Charette M, Reid R, et al. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother Oncol. 2005;75(3):258-270.
40. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA). Eur J Cancer. 2011;47(suppl 2). Abstract 1LBA.
41. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum. Pathol. 2000;31:578-583.